Pfizer (NYSE:PFE) Trading 1% Higher

Pfizer Inc. (NYSE:PFE)’s stock price traded up 1% during trading on Friday . The stock traded as high as $29.14 and last traded at $28.96. 7,993,426 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 39,845,512 shares. The stock had previously closed at $28.66.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday. Barclays increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $35.69.

Pfizer Trading Up 1.3 %

The company’s 50 day moving average price is $28.23 and its 200 day moving average price is $27.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The company has a market cap of $164.56 billion, a price-to-earnings ratio of -484.33, a price-to-earnings-growth ratio of 1.11 and a beta of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue was down 19.5% compared to the same quarter last year. During the same period last year, the business posted $1.23 EPS. Research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Raleigh Capital Management Inc. grew its position in shares of Pfizer by 2.3% during the 3rd quarter. Raleigh Capital Management Inc. now owns 66,751 shares of the biopharmaceutical company’s stock worth $2,214,000 after buying an additional 1,484 shares during the period. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Arden Trust Co grew its position in shares of Pfizer by 11.1% during the 4th quarter. Arden Trust Co now owns 43,872 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 4,369 shares during the period. Finally, DNB Asset Management AS grew its holdings in Pfizer by 5.0% during the fourth quarter. DNB Asset Management AS now owns 3,227,396 shares of the biopharmaceutical company’s stock valued at $92,917,000 after purchasing an additional 153,719 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.